Denver PWM’s Denali Therapeutics DNLI Stock Holding History

Denver PWM’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-80	Closed	-$1.63K	–	117
2024 Q4	$1.63K	Buy	+80	New	+$2.05K	﹤0.01%	197

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Denver PWM's DNLI Position: Q1 2025 in Review

Denver PWM sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 80 shares — an estimated $1.63K sold.

Denver PWM first reported a position in DNLI in Q4 2024 and held it in 1 quarter. The position peaked at $1.63K in Q4 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Denver PWM reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Denver PWM sold 80 Denali Therapeutics shares in Q1 2025, an estimated $1.63K.
Denver PWM first reported a position in Denali Therapeutics in Q4 2024 and held it in 1 quarter.
Denver PWM's Denali Therapeutics position peaked at $1.63K in Q4 2024.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Denver PWM's 13F filing for Q1 2025, filed 7 May 2025.